DOI: 10.5176/2345-783X_PHARMA17.42
Authors: Dr. Sunny Johnson, Krystal Persaud, Muhammad Ali, Khushabu Nayak, Ovais Syed, Dr. Maria Jerald
Abstract:
Bipolar Disorder (BD) is a chronic, debilitating, psychiatric disease that presents a heavy burden on the lives of patients as well as their caregivers. In Bipolar I Disorder, depressive episodes dominate manic episodes in terms of severity and frequency, thereby causing patients to seek initial treatment for the depressive symptoms. Until recently, there were minimal options available for treating Bipolar Depression. Lurasidone (Latuda) was solely indicated for Adult Schizophrenia, but as of July 1, 2013, it was approved by the FDA to treat Bipolar Depression as monotherapy or adjunctively with Lithium or Valproate. In this article, we will examine the efficacy of using Lurasidone in treating patients with BD, and its effect on depression and quality of life. Lurasidone has shown to have an excellent outcome when used to treat the depressive symptoms that patients of BD suffer from.
Keywords: component; Bipolar Disorder; Depression; Lurasidone
Updating...